Allarity Therapeutics Inc. (NASDAQ: ALLR) announced that enrollment has opened for a Phase 2 clinical trial evaluating stenoparib combined with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE